Expression and location of intracellular tissue factor in atherosclerosis stable plaque of ApoE^−/− mice

Abstract

In the ApoE^−/− mouse model of atherosclerosis (AS) stable plaque, the expression and location of intracellular tissue factor (TF) in the cellular components of AS stable plaque were investigated in order to explore the cellular mechanism of AS thrombosis. Pathological changes of the stable plaque were observed under a microscope. The expression of TF protein was examined in aortic stable plaque of mice by using immunohistochemistry. Color image planimetric system was used to analyze the histological components of the stable plaque and the TF distribution. Under the confocal microscope, the intracellular TF location in the stable plaque of mice was observed. The results showed the cellular area was the major part of stable plaque (67.36%±6.52%, P<0.01). The percentage of total area occupied by cellular area was significantly larger than atheromatous gruel and acellular area (P<0.01). Macrophages and smooth muscle cells (SMC) were major cells in the cellular area. The percentage of total area occupied by SMC was significantly larger than by macrophages (P<0.01). Multiple linear regression analysis showed there was a positive correlation between TF area and SMC area (r=0.616, P=0.008), and no correlation was found between TF area and macrophage area (r=0.437, P=0.08). Pictures of color image planimetric analysis of TF and SMC were merged to highlight areas with co-localization (yellow), it was concluded that the process could be a cell-mediated TF expression in the stable plaque. SMC may be the major source of TF in AS without plaque rupture.

Keywords

atherosclerosis / stable plaque / tissue factor / Apo E knockout mice

References

[1] Viles-GonzalezJ.F., FusterV., BadimonJ.J.. Links between inflammation and thrombogenicity in atherosclerosis. Curr Mol Med, 2006, 6(5): 489-499

[2] MarutsukaK., HatakeyamaK., YamashitaA., et al.. Role of thrombogenic factors in the development of atherosclerosis. J Atheroscler Thromb, 2005, 12(1): 1-8

[3] Viles-GonzalezJ.F., AnandS.X., ZafarM.U., et al.. Tissue factor coagulation pathway: a new therapeutic target in atherothrombosis. J Cardiovasc Pharmacol, 2004, 43(5): 669-676

[4] CrawleyJ., LupuF., WestmuckettA.D., et al.. Expression, localization, and activity of tissue factor pathway inhibitor in normal and atherosclerotic human vessels. Arterioscler Thromb Vasc Biol, 2000, 20(5): 1362-1373

[5] ThiruvikramanS.V., GuhaA., RobozJ., et al.. In situ localization of tissue factor in human atherosclerotic plaques by binding of digoxigenin-labeled factors VIIa and X. Lab Invest, 1997, 76(2): 297-299

[6] MorenoP.R., MurciaA.M., PalaciosI.F., et al.. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation, 2000, 102(18): 2180-2184

[7] TedguiA., MallatZ.. Smooth muscle cell: another source of tissue factor-containing microparticles in atherothrombosis?. Circ Res, 2000, 87(2): 81-82

[8] ToschiV., GalloR., LettinoM., et al.. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation, 1997, 95(3): 594-599

[9] StollG., BendszusM.. Inflammation and atherosclerosis: novel insights into plaque formation and destabilization. Stroke, 2006, 37(7): 1923-1932

[10] VirmaniR., BurkeA.P., FarbA.. Sudden cardiac death. Cardiovasc Pathol, 2001, 10(5): 211-218

[11] VirmaniR., BurkeA.P., FarbA.. Plaque rupture and plaque erosion. Thromb Haemost, 1999, 82(Suppl1): 1-3

[12] WuP.S., ZhangY.H., XuY.K., et al.. The new definition and risk stratification of vulnerable plaque and vulnerable patient. Chin J Cardiol (Chinese), 2004, 32(3): 283-285

[13] WenC., XuH., ChenK.J., et al.. On establishment and assessment of experimental vulnerable plaque animal models. CJITWM (Chinese), 2005, 25(9): 856-859

[14] GiesenP., NemersonY.. Tissue factor on the loose. Seminars in Thrombosis and Hemostasis., 2000, 26(4): 379-384

[15] JudeB., ZawadzkiC., SusenS., et al.. Relevance of tissue factor in cardiovascular disease. Arch Mal Coeur Vaiss, 2005, 98(6): 667-671

[16] LazarusR.A., OliveroA.G., EigenbrotC., et al.. Inhibitors of tissue factor VIIa for anticoagulant therapy. Curr Med Chem, 2004, 11(17): 2275-2290

[17] CirilloP., CaliG., GolinoP., et al.. Tissue factor binding of activated factor VII triggers smooth muscle cell proliferation via extracellular signal-regulated kinase activation. Circulation, 2004, 109(23): 2911-2916

[18] HankeH., LenzC., FinkingG.. The discovery of the pathophysiological aspects of atherosclerosis-a review. Acta Chir Belg, 2001, 101(4): 162-169

[19] RudijantoA.. The role of vascular smooth muscle cells on the pathogenesis of atherosclerosis. Acta Med Indones, 2007, 39(2): 86-93

[20] HongM., HuangR.B., YaoJ.X., et al.. Role of homocysteine in tissue factor expression in human vascular smooth muscle cells. Chin J Pathophysiol (Chinese), 2007, 23(11): 2081-2085

[21] SmithJ.D.. Mouse models of atherosclerosis. Lab Anim Sci, 1998, 48(6): 573-579

[22] SmithJ.D., BreslowJ.L.. The Emergence of mouse models of atherosclerosis and their relevance to clinical research. J Intern Med, 1997, 242(2): 99-109